The Daily Biotech Pulse: ImmunityBio Reports Positive Readout, Valneva Starts Late-Stage Chikungunya Vaccine Study, Sio Gene Shelves Parkinson’s Program
Here's a roundup of top developments in the biotech space over the last 24 hours:
Inventiva Posts Results of Clinical Thorough QT Study Of Lanifibranor
Inventiva (NASDAQ:IVA) announced the results of a clinical thorough QT/QTc study demonstrating the safety of lanifibranor on cardiac electrical activity. The…
Inventiva Announces Design Of LEGEND Phase IIa Combination Trial With lanifibranor And SGLT2 Inhibitor Empagliflozin In Patients With NASH And Type 2 Diabetes
The LEGEND trial is a proof-of-concept Phase IIa clinical trial to evaluate the safety and efficacy of lanifibranor in combination with the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin
Inventiva Highlights Results Of Its NATIVE Phase 2b Trial With Lanifibranor In NASH Published In New England Journal Of Medicine
In the Phase IIb NATIVE, lanifibranor met both the primary and key secondary endpoints, including NASH resolution with no worsening of fibrosis and improvement of liver fibrosis with no worsening of NASH
NATIVE was
The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 20)
Fast Track Status Expanded For Inventiva’s NASH Treatment
The FDA has decided that the Fast Track designation previously granted to Inventiva SA’s (NASDAQ:IVA) lanifibranor in NASH encompasses the treatment…
HC Wainwright & Co. Maintains Buy on Inventiva, Raises Price Target to $40
HC Wainwright & Co. analyst Ed Arce maintains Inventiva (NASDAQ:IVA) with a Buy and raises the price target from $38 to $40.
Earnings Scheduled For September 20, 2021
Companies Reporting Before The Bell
• Cognyte Software (NASDAQ:CGNT) is expected to report quarterly earnings at $0.15 per share on revenue of $115.57 million.
The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi’s Pemphigus Trial Disappointment, Humanigen’s COVID-19 Drug Denied Emergency Use Authorization
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 8)
The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 11)